Tech Company Financing Transactions
FibroGen Funding Round
On 2/16/2005, FibroGen raised $100 million in funding from Adage Capital Management, Apothecary Capital and Brookside Capital.
Transaction Overview
Company Name
Announced On
2/16/2005
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Funds are expected to be used to increase staffing and the scope of FibroGen's clinical activities including expansion of anemia programs and continuation of studies in idiopathic pulmonary fibrosis and diabetic nephropathy.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
409 Illinois St.
San Francisco, CA 94158
USA
San Francisco, CA 94158
USA
Phone
Website
Email Address
Overview
FibroGen, a research-based biotechfirm, uses its expertise CTGF and HIF biology to discover, develop, and commercialize novel therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Enrique Conterno
Chief Financial Officer
Pat Cotroneo
Chief Medical Officer
Peony Yu
Vice President
Elias Kouchakji
Vice President
Al Lin
Vice President
James Polarek
VP - Engineering
Michael Martinelli
VP - General Counsel
Michael Lowenstein
VP - Human Resources
Richard Farley
VP - Operations
Christine Chung
VP - Regulatory Affairs
Wayne Frost
Browse more venture capital transactions:
Prev: 2/16/2005: Sandburst venture capital transaction
Next: 2/17/2005: Solidcore Systems venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs